Jim Cramer's 'Mad Money' Recap: Got Growth?
NEW YORK (TheStreet) -- Where can investors find the best growth stocks? All over place, if you know where to look, Jim Cramer said on "Mad Money" Tuesday.
In the biotech space, Cramer called out Regeneron
Restaurants Red Robin Gourmet Burgers
Cramer said just about any stock that deals with mobile, social media or the cloud is growing like gangbusters -- which leads right to this week's Twitter IPO. Just a few weeks ago, Cramer noted, he was at the high end of the range, saying Twitter could be worth up to $20 billion. But today, despite nothing factually changing, $20 billion seems at the low end of the range, with some calling for valuations as high as $50 billion for Twitter.
Cramer said that's a recipe for investors to get hurt, a la the Facebook
Cramer said he's willing to pay up to $28 a share for Twitter and not a penny more.
In the "Executive Decision" segment, Cramer sat down with Dr. Ron Cohen, president and CEO of Acorda Therapeutics
Cohen said sales of Acorda's multiple sclerosis drug, Ampyra, is the engine that's helping to drive the company forward and Acorda is very fortunate to have such a successful product. Acorda is not a one-hit wonder, however, as the company now has six drugs in clinical studies, including new formulations of ingredients of Amypra that may treat strokes and other conditions.